Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Network meta-analysis comparison of 5 first-line therapies for PFS

From: Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis

AI

0.51(0.38–0.69)

0.59(0.51–0.68)

0.57(0.48–0.67)

0.53(0.43–0.65)

1.96(1.45–2.64)

dalpi + Al

1.16(0.83–1.61)

1.12(0.79–1.57)

1.03(0.72–1.48)

1.70(1.46–1.96)

0.87(0.62–1.21)

palbo + Al

0.97(0.78–1.20)

0.89(0.69–1.15)

1.76(1.49–2.07)

0.90(0.64–1.26)

1.04(0.83–1.29)

ribo + AI

0.92(0.71–1.20)

1.90(1.54–2.34)

0.97(0.67–1.39)

1.12(0.87–1.45)

1.08(0.83–1.41)

abema + AI

  1. dalpi dalpiciclib, palbo palbociclib, abema abemaciclib, ribo ribociclib, AI aromatase inhibitor, PFS Progression-free survival
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us